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ABSTRACT 
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Over the last few years, 
microRNAs (miRNAs) have emerged as master regulators of gene expression in cardiovascular biology and di-
sease. miRNAs are small endogenous non-coding RNAs that usually bind to 3′ untranslated region (UTR) of 
their target mRNAs and inhibit mRNA stability or translation of their target genes. miRNAs play a dynamic role 
in the pathophysiology of many CVDs through their effects on target mRNAs in vascular cells. Recently, nu-
merous miRNAs have been implicated in the regulation of the transforming growth factor-β (TGF-β)/bone mor-
phogenetic protein (BMP) signalling pathway which plays crucial roles in diverse biological processes, and is 
involved in pathogenesis of many diseases including CVD. This review gives an overview of current literature 
on the role of miRNAs targeting TGF-β/BMP signalling in vascular cells, including endothelial cells and smooth 
muscle cells. We also provide insight into how this miRNA-mediated regulation of TGF-β/BMP signalling 
might be used to harness CVD.  
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INTRODUCTION 
Cardiovascular diseases (CVD) remains 
a predominant cause of morbidity and mor-
tality worldwide in spite of our advances in 
the understanding of the etiology (Cohen et 
al., 2000). Indeed, CVD are the number one 
cause of death throughout the world killing 
17.5 million people in 2012 (WHO, 2012). 
Although mortality rates related to CVD are 
significantly reduced due to the identifica-
tion of major risk factors such as obesity, 
dyslipidaemia, diabetes, and hypertension, 
the prevalence of heart disease is greatly ex-
panding (NHLBI, 2012). This impending 
burden of the disease is stressing the need for 
further insight into the molecular mecha-
nisms that contribute to the pathology of 
CVD as well as the search for innovative 
therapeutic agents for CVD prevention and 
treatment.  
microRNAs (miRNAs) are endogenous, 
well conserved, small noncoding RNA mol-
ecules (20–25 nucleotides) that regulate the 
expression of approximately 60 % of the 
mammalian genes at post-transcriptional lev-
el (Lewis et al., 2005; Friedman et al., 2009). 
EXCLI Journal 2015;14:832-850 – ISSN 1611-2156 
Received: June 22, 2015, accepted: June 30, 2015, published: July 10, 2015 
 
 
833 
It is well established that miRNAs bind to 
conserved regions in the 3′ untranslated re-
gion (UTR) of their target mRNAs and in-
hibit either mRNA stability or the translation 
of their target genes in a tissue- and devel-
opment-specific manner. Each miRNA can 
target multiple mRNAs and numerous miR-
NAs can regulate one target mRNA, demon-
strating the huge combinatorial complexity 
and regulatory potential of miRNAs (Bartel, 
2009; Dombkowski et al., 2011). Both basic 
and clinical studies have demonstrated that 
miRNAs are involved in a diversity of bio-
logical processes such as apoptosis, prolifer-
ation, migration, and differentiation (van 
Rooij, 2011). miRNAs are expressed in a tis-
sue-, time- and context-dependent manner 
and can there by regulate many pathophysio-
logical processes. Recent studies show that 
miRNAs are highly expressed in vascular 
cells and play crucial role in the development 
and progression of CVD. Understanding the 
effect miRNAs have on key transcription 
factors or genes that are associated with 
CVD will be pivotal for the development of 
innovative therapeutic strategies to treat 
CVD patients.  
Members of transforming growth factor β 
(TGF-β) family play key roles in many dis-
eases, including CVDs such as hypertension, 
atherosclerosis, arteriovenous malformations 
(AVMs), and aneurysms (ten Dijke and Ar-
thur, 2007; Pardali et al., 2010; Doetschman 
et al., 2012). TGF-β family members have 
been implicated in controlling vascular mor-
phogenesis and function. In vitro as well as 
in vivo studies have shown their important 
role in controlling vascular cells, including 
endothelial and mural cell proliferation, mi-
gration, and apoptosis (Heldin et al., 1997; 
Heldin and Moustakas, 2012). Like in other 
biological processes, TGF-β family members 
exert their effects on vascular cells in a time 
and context-dependent manner (Pardali and 
ten Dijke, 2012; Akhurst, 2012). Recent re-
ports demonstrated that TGF-β signalling 
plays critical role in the regulation of several 
miRNAs. Moreover, numerous miRNAs also 
control expression of several members of the 
TGF-β family. 
In this review, we summarize the recent 
advances on miRNAs that control TGF-β 
signalling in (cardio)vascular diseases. We 
only discuss briefly about the regulation of 
miRNAs by TGF-β, as this is covered by ex-
cellent recent reviews (Ha and Kim, 2014; 
Hata and Liebermann, 2015). We focus on 
the miRNAs that regulate TGF-β signalling 
in vascular cells, including endothelial cells 
(ECs) and smooth muscle cells (SMCs). We 
centre our review on two vascular diseases 
that are caused by perturbation in TGF-β 
family signalling, i.e. hereditary haemor-
rhagic telangiectasia (HHT) and pulmonary 
arterial hypertension (PAH), two haploinsuf-
ficiency diseases of which patients can have 
inactivating mutations in one allele of a 
TGF-β family (co)receptor. Inhibition of 
miRNAs that target these receptors may re-
store their expression to normal levels, 
which may be of therapeutic benefit.  
 
TGF-β SIGNALLING 
TGF-β signalling is involved in a vast 
majority of cellular processes and plays cru-
cial role throughout life starting from gastru-
lation and body axis asymmetry to organ-
specific morphogenesis and adult tissue ho-
meostasis. The human TGF-β superfamily 
comprises 33 evolutionarily conserved plei-
otropic cytokines including three TGF-β 
isoforms, activins, growth and differentiation 
factors (GDFs), and bone morphogenetic 
proteins (BMPs). TGF-β family members 
regulate many key cellular processes such as 
cell division, differentiation, migration, ad-
hesion, organization and death, extracellular 
matrix (ECM) production, tissue homeosta-
sis and embryogenesis in a context- and cell 
type-dependent manner. Disruption of TGF-
β signalling has been implicated in several 
developmental disorders and diseases, in-
cluding cancer, fibrosis, auto-immune and 
CVDs (Heldin et al., 1997; Heldin and 
Moustakas, 2012; Shi and Massagué, 2003; 
Schmierer and Hill, 2007; Goumans et al., 
2009; Derynck and Miazono, 2008).  
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All TGF-β ligands are secreted in an in-
active form, but become biologically active 
when carboxy- terminal mature domain is re-
leased from interacting with the amino-
terminal pro-domain. The biologically active 
TGF-β ligand is a dimer (ten Dijke et al., 
2007; Chang et al., 2002). TGF-β family 
members regulate multiple cell signalling 
pathways by binding to a complex of two 
type II and two type I serine/threonine kinase 
transmembrane receptors and signals through 
both Smad-dependent and Smad-
independent pathways. For example, differ-
ent factors regulate the TGF-β/Smad signal-
ling pathway in multiple steps. In mammals, 
seven type I receptors, also known as activin 
receptor-like kinases (ALKs), and five type 
II receptors have been reported (Heldin et al., 
1997; Shi and Massagué, 2003; Schmierer 
and Hill, 2007). Besides the two signalling 
receptors, also two co-receptors, betaglycan 
and endoglin, have been identified that pre-
sent ligands to the type I and type II recep-
tors (Goumans et al., 2009; Wong et al., 
2000). 
Upon binding of the ligand, the type II 
receptor recruits and phosphorylates the type 
I receptor on specific serine and threonine 
residues in the intracellular juxtamembrane 
region. Signalling in most cells by TGF-β 
occurs through TGF-β type II receptor 
(TβRII) and TβRI (also termed activin recep-
tor like kinase (ALK)5) complex, activins 
through activin receptor type IIA (ActRIIA), 
ActRIIB and ALK4, and BMPs through 
BMP type II receptor (BMPRII), ActRIIs 
and ALK1, 2, 3 and 6. However, TGF-β can 
signal via both ALK1 and ALK5 in ECs 
(Goumans et al., 2002). Activation of the 
type I receptor results in recruitment and 
phosphorylation of receptor-regulated Smads 
(R-Smads) at the two serine residues located 
in their extreme carboxyl termini. ALK4, 5 
and 7 mediate R-Smad2 and 3 phosphoryla-
tion, whereas ALK1, 2, 3 and 6 induce phos-
phorylation of the R-Smads 1, 5 and 8. Acti-
vated R-Smads form complexes with the 
coSmad i.e. Smad4 which translocate into 
the nucleus where they act as transcription 
factors and regulate transcription of target 
genes. Inhibitory (I) Smads, i.e. Smad6 and -
7 are known to compete with R-Smads for 
type I receptor interaction and mediate pro-
teosomal degradation of type I receptors by 
recruiting Smurf1/2 E3 ubiquitin ligases, and 
thereby mitigate activation of the R-Smads 
(Heldin et al., 1997; Heldin and Moustakas, 
2012; Shi and Massagué, 2003; Schmierer 
and Hill, 2007; Goumans et al., 2009). For a 
more detailed description of TGF-β signal-
ling, which is not discussed thoroughly here, 
we refer to recent reviews (Hata Hata and 
Liebermann, 2015; Euler, 2015; Zhang et al., 
2013; Cai et al., 2012). A schematic repre-
sentation of TGF-β/BMP signalling is de-
picted in Figure 1. 
 
TGF-β signalling in vascular cells 
Endothelial cells 
TGF-β signalling has been implicated in 
vascular development during embryogenesis, 
postnatal angiogenesis, and in maintenance 
of homeostasis during adult life. Mice defi-
cient in TGF-β and TGF- β receptors die dur-
ing embryogenesis due to defects in yolk sac 
angiogenesis (Dickson et al., 1995; Oshima 
et al., 1996; Larsson et al., 2001). Endotheli-
al specific knock out of TβRII or ALK5 
mimics the total knock out, demonstrating 
the importance of TGF-β signalling in endo-
thelial cells (Carvalho et al., 2007). TGF-β 
modulates proliferation, migration, apopto-
sis, permeability and morphogenesis of en-
dothelial cells (ECs) (Pardali and ten Dijke, 
2012). Increased levels of circulating TGF-β 
has been found in several CVD, including 
PAH, HHT, obesity and diabetes (ten Dijke 
et al., 2008). Interestingly, elevated circulat-
ing TGF-β promotes oxidative stress and 
dysfunction in apolipoprotein E-knockout 
(ApoE-KO) mice. However, TGF-β can acts 
either be protective or detrimental in ECs 
depending on the cell and context (Yan et al., 
2014).  
TGF‐β plays a crucial role in the regula-
tion of activation state of ECs through acti-
vation of two type I receptors, ALK5 and 
ALK1. ALK5 is broadly expressed in many 
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tissues, while the expression of ALK1 is 
largely restricted to the endothelium. It has 
been demonstrated that stimulation of ALK1 
triggers the phosphorylation of Smad1/5/8, 
whereas ALK5 induces Smad2/3 phosphory-
lation in ECs (Goumans et al., 2002). ALK1 
and ALK5 interact with each other and elicit 
opposite responses in ECs which eventually 
results in a fine tune EC function. Of note, 
mutations in the ALK1 or endoglin are 
 
 
Figure 1: TGF-β superfamily signalling 
TGF-β, activin or nodal ligands binds to a type II receptor dimer, which then recruit a type I receptor 
dimer. The type II receptor phosphorylates serine residues of the type I receptors leading to activation 
of the protein. Activated type I receptors phosphorylate its downstream targets SMAD2/3 (i.e. R-
Smads) which then form hetero-oligomeric complexes with the co-SMAD, SMAD4 and translocate to 
the nucleus to bind DNA at sequence-specific DNA motifs to regulate gene expression. The heter-
omeric SMAD complex also interacts with various co-regulators for transcriptional activation or repres-
sion. SMAD7 can inhibit the phosphorylation of SMAD2 and SMAD3. BMP signalling functions in a 
similar pattern. BMP6 and BMP7 bind to their type II receptor which then recruits the type I receptors, 
ALK3 or ALK6. In contrast, BMP2 and BMP4 bind first to their type I receptor which then recruits the 
type II receptor ACTRII or BMPRII. Activation of the receptor complex results in phosphorylation of the 
receptors and then leads to phosphorylation of SMAD1/5/8 which form hetero-oligomeric complexes 
with the SMAD4. The heteromeric SMAD complex translocate to the nucleus to bind DNA at specific 
DNA motifs and thereby regulate BMP-target genes. Co-regulators might interact with this complex 
and modulate BMP-mediated gene expression. SMAD6/7 can inhibit the phosphorylation of 
SMAD1/5/8 and subsequently inhibit BMP pathway.  
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associated with the vascular disorder HHT. 
In addition to these canonical signalling 
pathways, TGF‐β may also regulate biologi-
cal functions in a non-Smad dependent man-
ner such as nicotinamide adenine dinucleo-
tide phosphate (NADPH) oxidase-dependent 
redox mechanisms (Yan et al., 2014).  
Several lines of evidence show that TGF-
β can stimulate or inhibit angiogenesis in 
vitro and in vivo, depending on the experi-
mental setup. For example, TGF-β/ALK5 
signalling inhibits angiogenesis by inhibiting 
EC proliferation, migration and tube for-
mation in a Smad dependent manner (Gou-
mans et al., 2002, 2003). Activation of 
ALK5 inhibits migration of ECs through en-
hanced expression of fibronectin and plas-
minogen activator inhibitor type 1 (PAI-1). 
ALK5 has also been involved in vascular 
permeability through modulation of tight 
junction protein Claudin-5 (Ota et al., 2002). 
Indeed, ALK5 augments TGF-β mediated 
vascular permeability and plays critical role 
in actin cytoskeleton remodelling. Further-
more, TGF-β/ALK5 signalling is also impli-
cated in stabilization of the vessel wall via 
increased expression of VE-cadherin 
(Birukova et al., 2005; Rudini et al., 2008). 
TGF-β induces apoptosis in pulmonary mi-
crovascular ECs, which involves the ALK5-
Smad2 pathway and decreased expression of 
the anti-apoptotic genes Bcl-2 and cFLIP. In 
contrast, several other reports demonstrated 
the role of the p38 mitogen-activated protein 
kinase (MAPK) pathway in regulation of 
TGF-β-induced EC apoptosis (Hyman et al., 
2002; Ferrari et al., 2006). These observa-
tions demonstrate that TGF-β signalling reg-
ulates EC functions in a specific ligand- and 
context-dependent manner.  
BMPs also play crucial role in the modu-
lation of EC function. Cumulative evidence 
shows that BMP4, BMP6 and BMP9 are in-
volved in proliferation, migration and angio-
genesis of ECs (Valdimarsdottir et al., 2002, 
Suzuki et al., 2008). Inhibition of the 
BMPRII expression in ECs resulted in re-
duced phosphorylation of Smad1/5/8 and Id1 
expression following hypoxia. Interestingly, 
similar characteristics were observed in the 
ECs from PAH. Indeed, mutations in 
BMPR2 are observed in ~80 % of patients of 
hereditary PAH (Teichert-Kuliszewska et al., 
2006). Therefore, developing new therapeu-
tic strategies that lead to an increase in cell 
surface BMPRII expression might be benefi-
cial for these patients. The TGF-β co-
receptor endoglin regulates the proliferation, 
migration, apoptosis and angiogenesis of 
ECs. It has been demonstrated that ECs de-
rived from endoglin deficient embryos have 
reduced proliferation and migration capaci-
ties (Goumans et al., 2009; Yan et al., 2014). 
Interestingly, the vascular dysfunction in 
pre-eclampsia is in part caused by the pres-
ence of high levels of soluble endoglin (ten 
Dijke and Arthur, 2007). 
 
Smooth muscle cells 
Several type I and type II receptors of the 
TGF-β family are expressed in vascular 
SMCs (VSMCs). Numerous studies reported 
that TGF-β/Smad signalling plays key role in 
differentiation and “phenotype switching” of 
SMCs via modulation of a large set of SMC 
differentiation marker genes such as SM-
actin, SM22α and calponin (Owens et al., 
1995). Disruption of TGF-β signalling leads 
to defective vessels losing integrity of the 
vessel wall due to the failure in recruitment 
and differentiation of SMCs. Genetic dele-
tion of TβRII specifically in VSMCs resulted 
in vascular defects in the yolk sac; however, 
these were observed at later stages of devel-
opment than the total knock out (Carvalho et 
al., 2007). Whereas mice completely deplet-
ed of TβRII die at E10.5, embryos without 
TβRII in VSMCs are able to survive till 
E12.5. Besides its role during development, 
TGF-β is an important regulator of the dif-
ferentiation status of SMCs in adult animals. 
For detailed description of the effect of TGF-
β signalling on SMC differentiation we like 
to refer to Guo and Chen (2012).  
Myocardin, a coactivator of serum re-
sponse factor and δEF, a zinc finger E-box 
binding transcription factor, have been 
shown to increase TGF-β/Smad-3 induced 
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activation of SM22α expression (Qiu et al., 
2005; Nishimura et al., 2006). TGF-β also 
blocks proliferation of VSMCs via 
ALK5/Smad3/p38 MAPK pathway. Howev-
er, TGF-β inhibits migration of SMCs in a 
Smad3-independent manner through en-
hanced expression of cysteine rich protein 2 
(Lin et al., 2008). Interestingly, SMCs de-
rived from Smad3-deficient mice show re-
duced inhibition of proliferation, but no ef-
fect on migration following treatment with 
TGF-β (Kobayashi et al., 2005). Recent stud-
ies reported that activation of TGF-β/Smad3 
pathway inhibit VSMC apoptosis through an 
autocrine signalling mechanism involving 
VEGF-A following angioplasty (Shi et al., 
2014).  
Endoglin and BMPs also play an im-
portant role in the formation, differentiation 
and function of VSMCs. The BMP signal-
ling pathway is also implicated in the induc-
tion and maintenance of the contractile 
SMCs and loss of BMP signalling is associ-
ated with abnormalities in vascular devel-
opment and in vascular proliferative condi-
tions, such as restenosis and PAH (Interna-
tional PPH Consortium et al., 2000; Koehler 
et al., 2004). The effect BMP has on VSMCs 
is context dependent. BMP2 and BMP7 can 
inhibit proliferation of VSMCs whereas 
BMP2 promotes migration of VSMCs. How-
ever, BMP4 and BMP7 trigger apoptosis via 
a caspase 8/9-dependent mechanism in pul-
monary SMCs, demonstrating that how 
BMPs effect the function of SMCs is de-
pending on the source of SMCs and their lo-
cal environment (Lagna et al., 2006; Gou-
mans et al., 2009; Cai et al., 2012).  
 
TGF-β REGULATION OF miRNAs IN 
VASCULAR CELLS 
While miRNAs regulate the expression 
of several members of the TGF-β signalling 
pathway, TGF-β itself can modulate the ex-
pression of numerous miRNAs in multiple 
cell types. TGF-β regulates their expression 
by binding to p68, a component of the 
Drosha microprocessor complex (Butz et al., 
2012; Davis et al., 2008). MiRNAs that are 
regulated by TGF-β in vascular cells are 
summarized in Table 1. 
 
REGULATION OF MEMBERS OF THE 
TGF-β SUPERFAMILY BY miRNAs IN 
VASCULAR CELLS 
Although several predictions were made 
for potential miRNAs that target members of 
TGF-β family based on in silico analysis, 
experimental validation is crucial. Numerous 
recent studies show that several miRNAs 
target components of TGF-β signalling 
pathway in multiple cells including ECs and 
SMCs, and play a pivotal role in the patho-
genesis of a variety of vascular diseases. 
miRNAs targeting TGF-β signalling pathway 
in vascular cells and associated vascular dis-
eases are summarized in Table 2. 
 
 
 
Table 1: miRNAs that are regulated by TGF-β/BMP signalling pathway in vascular cells 
MicroRNA Expression Tissue/Cell Reference 
let-7d Decreased Idiopathic fibrosis pulmonary tissue Pandit et al., 2010 
miR-21 Increased ECs Kumarswamy et al., 2012 
miR-24 Increased Cardiac fibroblasts Wang et al., 2012b 
miR-27b Decreased Cardiomyocytes Wang et al., 2012a 
miR-29a  Increased ECs Wang et al., 2013a 
miR-143/145 Increased Coronary artery SMCs Long and Miano, 2011 
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Table 2: miRNAs targeting TGF-β/BMP signalling pathway in vascular cells 
 MicroRNA Target Disease / Process involved Reference 
ECs 
Let-7g 
Thbs1, 
Tgfbr1, 
Smad2  
Cardio vascular disease,  
Endo-MT 
Liao et al., 2014;  
Chen et al., 2012 
miR-17/92 Bmpr2 PAH Brock et al., 2009 
miR-21 Tgf-β2, Bmpr2 
iPSCs differentiation,  
PH  Di Bernardini et al., 2014 
miR-27 and 
miR-205 Smad1/4 
PAH,  
HHT 
Drake et al., 2013;  
Tabruyn et al., 2013 
miR-26a Smad1 Acute myocardial infarction  Icli et al., 2013 
SMCs 
miR-17/92 Bmpr2, Smad5 PAH Pullamsetti et al., 2011 
miR-21 
Pdcd4,  
Dock-4/5/7, 
Bmpr2  
Vascular proliferative disor-
ders,  
PAH 
Kang et al., 2012;  
Ahmed et al., 2011;  
Yang et al., 2012 
miR-22 Tgfbr1 PAH Caruso et al., 2010 
miR-24 Trb3, Smad2/3 
Proliferation,  
Remodelling Chan et al., 2010 
miR-26 Smad1/4 Aneurysms Leeper et al., 2011 
miR-29b Elas-tin/MMP2 
Aneurysms,  
Marfan syndrome Merk et al., 2012 
miR-30 Runx2 Vascular calcification Balderman et al., 2012 
miR-96 Trb3 & oth-ers 
Atherosclerosis,  
Myocardial infarction  
Kim et al., 2014;  
Nishiguchi et al., 2015;  
Wang et al., 2013b 
miR-
143/145 Klf4/ Bmpr2 Atherosclerosis, PAH 
Davis-Dusenbery et al., 2011; 
Caruso et al., 2012 
miR-302 Bmpr2 PAH Kang et al., 2012b 
Other 
vascular 
cells 
miR-17/92 Vegf Second heart field Bai et al., 2013 
miR-21 Tgfbr3 Cardiac fibrosis Liang et al., 2012 
miR-133 Tgfb1 Atrial fibrillation Shan et al., 2009 
miR-155 AT1R Aneurysms,  Hypertension Zheng et al., 2010 
miR-181c Bmpr2 Ventricular septal defects , PAH Li et al., 2013  
miR-590 Tgfbr2 Atrial fibrillation Shan et al., 2009 
 
 
Endothelial cell miRNAs 
Endothelial cells are crucial for maintain-
ing vascular homeostasis. miRNAs are ex-
pressed in the vasculature and are indispen-
sable for endothelial regulation of vessel 
function through regulation of key pathways, 
including TGF-β/BMP signalling. We will 
now describe the most important miRNAs in 
more detail. 
 
Let-7g 
Members of the Let-7 family are highly-
conserved miRNAs and play crucial role in 
regulation of cell differentiation (Liao et al., 
2014). Although several studies implicate a 
role for the Let-7 family in many patholo-
gies, their role in CVD remains unknown. 
Recently, Liao et al. (2014)demonstrated the 
involvement of Let-7g, a well-studied mem-
bers of the Let-7 group, in ECs. Let-7g has 
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been shown to effect on multiple EC func-
tions through targeting three key components 
of TGF-β pathway. Overexpression of Let-
7g down-regulates the expression of throm-
bospondin 1(THBS1), Tgfbr1, and Smad2 
genes in ECs. TGF-β1 induced phosphoryla-
tion of Smad2 (pSmad2) is decreased upon 
overexpression of Let-7g in ECs. Converse-
ly, inhibition of Let-7g enhanced TGF-β1 
induced pSmad2, further suggesting that Let-
7g is a key player in the modulation of TGF-
β1 signalling in ECs. Ectopic expression of 
Let-7g significantly decreased vascular cell 
adhesion molecule-1 (VCAM-1) secretion, 
thereby inhibiting the monocyte adhesion to 
ECs. Moreover, Let-7g markedly attenuated 
inflammation and enhanced angiogenesis in 
a TGF-β dependent manner. Let-7g also re-
duces the expression of plasminogen activa-
tor inhibitor (PAI)-1 in ECs, an important 
downstream effector of the TGF-β pathway. 
Injection of Let-7g-expressing plasmids into 
ApoE-KO mice revealed that the protein lev-
els of PAI-1 and pSmad2 are decreased in 
the vessel wall. In contrast, inhibition of Let-
7g into ApoE-KO mice resulted in excessive 
growth of vascular intima-media, enhanced 
infiltration of macrophages, and induction of 
TGF-β downstream genes such as PAI-1 in 
the carotid arteries. In line with these obser-
vations, serum levels of Let-7g are inversely 
correlated with PAI-1 levels in lacunar 
stroke patients, who have EC dysfunction. 
Interestingly, Let-7g promotes senescence of 
ECs through augmenting sirtuin-1 (SIRT-1) 
protein levels. Based on these observations, 
Liao et al. (2014) proposed that Let-7g might 
be a potential target in CVD through its pro-
tective function in ECs via modulation of 
TGF-β signalling. 
Another study reported that fibroblast 
growth factor (FGF) signalling controls 
TGF-β signalling via regulation of let-7 ex-
pression in ECs (Chen et al., 2012). Basal 
FGF signalling is essential for maintaining 
the expression of let-7 in ECs. Disruption of 
the intracellular adaptor FGF receptor sub-
strate 2 (FRS2) of FGF signalling results in 
enhanced the expression of TβR1 and induc-
es pSmad2. Defective FGF signalling also 
induces the expression of let-7, which in turn 
inhibits TGF-β signalling and suppresses 
several markers of endothelial-to-mesen-
chymal transition (Endo-MT), a process in 
which endothelial cells lose their cobble 
stone morphology and start to express SMC 
markers. Endo-MT is pivotal process in-
volved in the formation of neointima for-
mation, which underlies in several diseases 
such as PAH, transplant vasculopathy, reste-
nosis, and atherosclerosis among others. 
Therefore, regulation of the FGF and TGF-β 
axis via let-7 may play a crucial role in ves-
sel wall homeostasis (Chen et al., 2012).  
 
miR-17/92 
PAH is a fatal disorder of the lung vascu-
lature characterized by enhanced prolifera-
tion of ECs and SMCs. Mutations in the 
BMPR2 gene have been identified in about 
80 % of hereditary PAH and 10–40 % of 
sporadic idiopathic PAH patients (Interna-
tional PPH Consortium et al., 2000; Koehler 
et al., 2004). The miRNA cluster 17/92 
(miR-17/92), containing six mature miRs: 
miR-17, miR-18a, miR-19a, miR-19b-1, 
miR-20a, and miR-92, has been shown to 
target the BMPR2 gene and reduces protein 
expression of BMPR2 as well as 3′-UTR ac-
tivity of BMPR2 (Brock et al., 2009). Inter-
estingly, the pro-inflammatory cytokine in-
terleukin (IL)-6 induces the expression of 
miR-17/92 cluster genes in human pulmo-
nary artery ECs (HPAECs). Knockdown of 
signal transducer and activator of transcrip-
tion (STAT)-3, a potential modulator of IL-6 
signalling, resulted in inhibition of the IL-6 
induced expression of miR-17/92. In agree-
ment with this, a highly conserved STAT3-
binding site was found in the promoter re-
gion of the miR-17/92 gene C13orf25. IL-6 
significantly increased the expression of 
C13orf25 through this distinct region. Fur-
thermore, it was shown that STAT3 activa-
tion results in reduced protein expression of 
BMPR2. These data indicate that the 
STAT3-miR-17/92 axis regulates BMPR2 
expression in HPAECs and therefore may be 
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useful as a target for designing therapeutic 
strategies for PAH to increase the reduced 
expression levels of BMPRII (Brock et al., 
2009). 
 
miR-21 
Cardiovascular regeneration is an essen-
tial repair or replacement process that in-
volves the regeneration of damaged vessels 
and formation of new vessels in the infarcted 
area. However, identification of a suitable 
EC cell source for cardiovascular regenera-
tion has proven to be extremely challenging. 
Recently, Di Bernardini et al. (2014) report-
ed that miR-21 regulates differentiation of 
inducible pluripotent stem cells (iPSCs) to 
ECs through directly targeting TGF-β2. 
TGF-β2 has been shown to be involved in 
inducing several EC markers and in tube 
formation in vitro in iPSCs. Overexpression 
of miR-21 in pre-differentiated iPSCs up-
regulates the expression of several EC mark-
ers, whereas inhibition of miR-21 exerts op-
posite effects. Ectopic expression of miR-21 
enhanced TGF-β2 expression. Knockdown 
of TGF-β2 attenuated miR-21 induced EC 
marker expression in iPSCs. These findings 
suggest that miR-21 in concert with TGF-β2 
regulates the differentiation of iPSCs into 
ECs (Di Bernardini et al., 2014).  
In addition to its important role in iPSCs 
differentiation, miR-21 is also implicated in 
pulmonary hypertension (PH) by regulating 
the BMP pathway in ECs (Parikh et al., 
2012). Parikh et al. (2012) identified miR-21 
as a potential player in PH using multiple 
approaches including network analysis, ro-
dent models and patient samples. In 
HPAECs, BMPR2 signalling induces the ex-
pression of miR-21 which in turn suppresses 
expression of BMPR2. In particular, BMP9 
induces the expression of miR-21 and 
knockdown of BMPR2 significantly miti-
gates miR-21 expression in HPAECs. In ad-
dition, knockdown of Smad5, a downstream 
effector of BMPRII signalling also decreases 
expression of miR-21. Interestingly, Smad4 
depletion did not influence miR-21 expres-
sion, suggesting that BMPR2 is required for 
inducing the expression of miR-21 upon 
BMP stimulation, and this process depends 
on certain, but not all, Smads (Parikh et al., 
2012). 
 
miR-27 and miR-205 
miR-27 has been shown to be expressed 
in vascular cells including ECs. In pulmo-
nary ECs, BMP9 strongly induces the ex-
pression of miR-27a (Drake et al., 2013). As 
PAH is associated with BMPR2 mutations 
accompanied by enhanced proliferation of 
ECs and SMCs, Drake et al. (2013) explored 
the effect of miR-27 on distinct PAH muta-
tions. They reported that miR-27a expression 
is decreased in ECs of PAH patients with 
different mutations of the BMPR2. However, 
treatment with ataluren, an investigational 
drug, significantly enhances miR-27 pro-
cessing across a range of nonsense PAH mu-
tations in a BMP dependent manner. Atalu-
ren has been shown to induce read through 
of nonsense mutations by altering ribosomal 
proofreading activity only on premature ter-
mination codons, but does not affect bona 
fide termination codons. Ataluren treatment 
enhances the protein levels of BMPR-II and 
subsequently phosphorylation of Smads. 
This results in correction of the BMP-
mediated miR processing and inhibits the 
excessive proliferation of pulmonary ECs 
and SMCs derived from PAH patients with 
nonsense mutations. These data identified 
ataluren as a capable drug to treat PAH as it 
can effectively suppresses BMPR2 and 
SMAD9 nonsense mutations and correct 
several aspects of BMP signalling through 
regulation of miR-27 in ECs (Drake et al., 
2013). 
In addition to its role in PAH, miR-27 
together with miR-205 has been implicated 
in HHT, which is an autosomal dominant 
vascular disorder that leads to formation of 
abnormal blood vessel formation and haem-
orrhages (Tabruyn et al., 2013; Dingenouts 
et al., 2015). When analysing the plasma of 
HHT1 and HHT2 patients, the expression 
level of miR-27a was higher whereas miR-
205 was lower compared to controls (Tabru-
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yn et al., 2013). Smad1 and Smad4 have 
been identified as targets of miR-205. In-
deed, ectopic expression of miR-205 reduces 
protein expression of Smad1 and Smad4, but 
not their mRNA levels. Conversely, inhibi-
tion of miR-205 strongly increases protein 
levels of Smad1 and Smad4, but mRNA lev-
els were not affected. Overexpression of 
miR-205 attenuates proliferation, migration 
and tube formation of ECs. These findings 
suggest that both miR-27a and miR-205 
might be useful as biomarkers as well as tar-
gets for treatment of HHT patients (Tabruyn 
et al., 2013). 
 
miR-26a 
The expression of miR-26a is induced in 
a murine model of acute myocardial infarc-
tion and also in patients with acute coronary 
syndromes (Icli et al., 2013). miR-26a spe-
cifically targets Smad1, but not other Smad 
family members, including Smad2, Smad4, 
and Smad7. Ectopic expression of miR-26a 
decreased the 3′-UTR activity of Smad1 
which results in reduced expression of Id1 
and enhanced expression of p21WAF/CIP 
and p27. Overexpression of miR-26a in ECs 
significantly enhanced the proliferation, but 
inhibited migration, tube formation and an-
giogenesis. In contrast, the inhibitor of miR-
26a displayed opposite effects. These in vitro 
results were further substantiated by in vivo 
findings in zebrafish and mice. In zebrafish, 
ectopic expression of miR-26a resulted in 
reduced formation of the caudal vein plexus, 
a BMP driven process, which was rescued by 
Smad1 overexpression. In mice, overexpres-
sion of miR-26a decreased expression of 
Smad1 in ECs as well as exercise-induced 
angiogenesis. Conversely, inhibition of miR-
26a enhanced expression of Smad1 and pro-
motes robust angiogenesis, which is associ-
ated with decreased myocardial infarct size 
and improved heart function, suggesting that 
miR-26a acts as a critical regulator of angio-
genesis in ECs in a Smad1 dependent man-
ner (Icli et al., 2013). 
 
Smooth muscle cell miRNAs 
As described above, TGF-β/BMP signal-
ling is implicated in the differentiation of 
SMCs into contractile SMCs. Many miRs 
are involved in the phenotypic switch of 
SMCs in diverse vascular pathologies such 
as restenosis, atherosclerosis, and PAH 
through regulation of TGF-β/BMP signal-
ling. The functional expression of miRs has 
been associated with development of SMCs. 
Indeed, a mounting body of evidence shows 
that lack of the miR processing enzyme 
‘Dicer’ in SMCs during development results 
in late embryonic lethality and haemorrhage, 
probably due to reduced proliferation and 
differentiation of SMCs (Albinsson et al., 
2010). We will discuss several microRNAs 
involved in SMC function in relation to 
TGF-β signalling in more detail. 
 
miR-17/92 
Although the miR-17/92 cluster has been 
implicated in ECs, recent reports suggest that 
this cluster is also involved in pulmonary ar-
tery SMCs (PASMCs) related to the pathol-
ogy of PAH (Pullamsetti et al., 2012). Pul-
lamsetti and colleagues (2012) studied the 
role of miR-17 in PAH using antagomiRs in 
both mouse and rat models of PAH. Alt-
hough the treatment with antagomiRs of 
miR-17 enhanced expression of BMPR2, it 
did not effect TGFβR2 mRNA levels. Smad5 
was also predicted to be a target of miR-17 
by in silico analysis, however treating ani-
mals with a miR-17 inhibitor did not effect 
Smad5 mRNA levels. Overall, these findings 
suggest that miR-17 regulates many genes, 
most likely influences different cell types of 
the lung and therefore miR-17 might serve as 
an effective target for the treatment of PH.  
 
miR-21 
Vascular proliferative disorders such as 
restenosis and vein graft disease are associ-
ated with excessive proliferation and migra-
tion of SMCs. There is compelling evidence 
that miR-21 is involved in modulation of 
SMC function. BMP-4 has been shown to 
induce the expression of miR-21 which in 
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turn triggers the expression of several SMC 
contractile genes by targeting programmed 
cell death 4 (PDCD4) (Kang et al., 2012a). It 
was also reported that miR-21 targets many 
members of the dedicator of cytokinesis 
(DOCK) superfamily. Overexpression of 
miR-21 decreases the expression of Dock-4, 
5 and 7 and thereby reduces the migration of 
cells through repressing the activity of 
GTPase Rac1, a known player in cytoskele-
tal organization and cell migration. Interest-
ingly, miR-21 modulates the contractile 
function of SMCs by targeting Dock-4 and 5 
through a Rac1-independent mechanism. Of 
note, miR-21 prevented the inhibitory effects 
of BMP4 on proliferation and migration of 
primary keratinocytes and HaCaT cells 
(Ahmed et al., 2011). This observed discrep-
ancy could be attributable to different cell 
types involved in distinct pathologies and re-
quires more research. Taken together these 
data suggest that miR-21 plays a key role in 
the phenotypic switch of SMCs through 
DOCK family proteins in a BMP dependent 
manner (Kang et al., 2012a). 
The study from Kang et al. (2012a) is 
further corroborated by a recent study on the 
role of miR-21 in SMC function. Stein et al. 
(2014) demonstrated that miR-21 plays a 
pivotal role in the thrombospondin-1 (TSP-
1) induced proliferation and migration of 
VSMCs. However, the activity of miR-21 is 
not essential for TSP-1 to induce the expres-
sion of prostenotic genes including TGF-β2 
(Stein et al., 2014). Further studies are war-
ranted to understand these findings.  
Although it has been reported that miR-
21 modulates PH through its effects on BMP 
signalling in HPAECs, another study showed 
that miR-21 also plays an essential role in 
PASMCs via BMP signalling, and thereby 
modulates hypoxia induced PH (Yang et al., 
2012). Yang et al. (2012) demonstrated that 
miR-21 expression is up-regulated in distal 
small arteries in the lungs of hypoxia-
exposed mice. Moreover, there is a recipro-
cal relationship between BMPR2 and miR-
21 expression, further supporting the previ-
ous observations. Furthermore, it was also 
shown that miR-21 induces proliferation of 
PASMCs, mostly like through modulation of 
BMP signalling. However, further research 
is necessary to validate the role of miR-21 in 
PASMCs.  
 
miR-22 
TGFBR1 has been identified as a target 
for miR-22, which is down-regulated after 
21 days in a rat hypoxic model of PAH and 
after 2 days in a monocrotaline injection 
model of PAH. Interestingly, TGF-β1 stimu-
lation of PASMCs induced down-regulation 
of miR-22 similar to hypoxic and mono-
crotaline-treated rats. More studies are re-
quired to investigate the role of miR-22 on 
TGFBR1 in PAH and also the effect of TGF-
β1 on miR-22 expression (Caruso et al., 
2010).  
 
miR-24 
PDGF-BB induces the expression of 
miR-24 in vascular SMCs (VSMCs) which 
subsequently reduces the expression of Trib-
bles-like protein-3 (Trb3). Inhibition of Trb3 
results in decreased TGF-β and BMP signal-
ling through reduced expression of Smad 
proteins and thereby induce synthetic pheno-
type in VSMCs (Chan et al., 2010). Inhibi-
tion of miR-24 induces Trb3 expression and 
pro-synthetic activity of PDGF signalling. In 
contrast, overexpression of miR-24 inhibits 
Trb3 in BMP-independent manner and re-
presses pSmads in BMP-dependent manner 
resulting in inhibition of the BMP-Smad 
pathway in PASMCs. Overexpression of 
miR-24 suppressed BMP4-induced SMA and 
Id3 expression. Ectopic expression of Trb3 
decreased the inhibitory effect of miR-24 on 
the BMP4-mediated induction of SMA and 
Id3, suggesting a potential role of the miR-
24-Trb3 axis in the regulation of the BMP 
pathway. Furthermore, miR-24 inhibits 
BMP4-mediated proliferation and BMP-4 
induced actin remodelling of PASMCs, indi-
cating a role of miR-24 in different pro-
contractile activities of the BMP4 pathway in 
VSMCs. Interestingly, miR-24 negatively 
regulates the expression of total Smad2, 
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Smad3, and pSmad2, and thereby inhibits the 
TGF-β-signalling pathway. miR-24 also in-
hibits the TGF-β-induced expression of miR-
21. Furthermore, PDGF-BB modulates the 
TGF-β-mediated pro-contractile function via 
regulation of Trb3 and Smads via up-
regulation of miR-24 (Chan et al., 2010).  
 
miR-26 
In addition to its potential role in ECs, 
miR-26a also plays crucial role in the ‘phe-
notypic switch’ of SMCs which plays a key 
role in the formation of abdominal aortic an-
eurysm (AAA) (Leeper et al., 2011). Ectopic 
expression of miR-26a abolished the differ-
entiation of SMCs whereas inhibition of 
miR-26a promoted differentiation and apop-
tosis accompanied by reduced proliferation 
and migration of SMCs. Overexpression of 
miR-26a reduced whereas inhibition of miR-
26a enhanced Smad signalling. Specifically, 
inhibition of miR-26a enhanced expression 
of Smad1 and Smad4 whereas overexpres-
sion of miR-26a abolished Smad1 expres-
sion. The expression of miR-26a is reduced 
in the aneurysm wall as tested in two mouse 
models of AAA, associated with a phenotyp-
ic switch of SMCs. miR-26a enhances pro-
liferation and inhibits differentiation and 
apoptosis of SMCs, and modulates TGF-β 
pathway. These findings suggest that miR-
26a plays a crucial role in SMC biology and 
might represent a potential therapeutic target 
in AAA disease (Leeper et al., 2011). 
 
miR-29b  
miR-29b is also implicated in the devel-
opment of aneurysms. It has been demon-
strated that miR-29b expression is induced in 
the ascending aorta of “Marfan” mice 
(Fbn1C1039G/+) (Merk et al., 2012). As-
cending aortas of Marfan mice displayed re-
duced and fragmented elastin protein levels 
and decreased mRNA levels of elastin and 
enhanced matrix metalloproteinase-2 (MMP-
2) expression and activity. Both elastin and 
matrix metallo-protease MMP-2 are identi-
fied as targets of miR-29b. Interestingly, 
NFκB, a pivotal inflammatory transcription 
factor acts as a repressor of miR-29b. TGF-β 
treatment inhibits NFκB and thereby en-
hances miR-29b expression aortic SMCs de-
rived from Marfan mice. In line with these 
results, treatment with an NFκB inhibitor 
augmented, whereas blocking TGF-β or 
losartan treatment strongly decreased the ex-
pression of miR-29b in Marfan mice. Inhibi-
tion of miR-29b resulted in reduced devel-
opment of aneurysms, aortic wall apoptosis, 
and extracellular matrix deficiencies. Taken 
together, this study identified miR-29b as a 
novel target for development of therapeutic 
strategies for aneurysms (Merk et al., 2012).  
 
miR-30 
Dedifferentiation of SMCs to an osteo-
blast-like phenotype may result in vascular 
calcification under some pathological condi-
tions. A miR microarray analysis identified 
miR-30b and miR-30c as miRs that regulate 
expression of Runx2, a key transcription fac-
tor involved in calcification. Treatment of 
SMCs with BMP-2 attenuates expression of 
miR-30b and miR-30c in SMCs (Balderman 
et al., 2012). In addition, it has been reported 
that miR-30b and miR-30c binds to the 3′-
UTR of Runx2. Consistent with this notion, 
antagomiRs targeting miR-30b and miR-30c 
significantly increased the expression of 
Runx2 and results in intracellular calcium 
deposition and mineralization. Moreover, ec-
topic expression of miR-30b and miR-30c 
reduced the expression of Runx2 and miner-
alization of SMCs. To substantiate these in 
vitro findings and to overrule the tissue cell 
culture effects, immune-histochemical stain-
ings were performed for expression of BMP-
2 and miR-30b in calcified human coronary 
arteries. They found that BMP-2 is highly 
expressed whereas miR-30b is lowly ex-
pressed in calcified human coronary arteries. 
This study supports the notion that BMP-2 
reduces the expression of miR-30b and miR-
30c to enhance expression of Runx2 in 
SMCs and thereby promote mineralization 
(Balderman et al., 2012). 
 
EXCLI Journal 2015;14:832-850 – ISSN 1611-2156 
Received: June 22, 2015, accepted: June 30, 2015, published: July 10, 2015 
 
 
844 
miR-96 
Another miR involved in phenotypic 
switch of SMCs is miR-96. BMP4 down-
regulates the expression of miR-96 in 
VSMCs. miR-96 targets Trb3 gene which 
regulates BMP signalling pathway. miR-96 
has been shown to induce contractile pheno-
type in VSMCs through regulation of SMC‐
specific genes. Because phenotype switching 
of SMCs is crucial in diseases such as ather-
osclerosis and restenosis, miR-96 might play 
a role in these diseases (Kim et al., 2014). 
Indeed, several recent studies suggest that 
miR-96 is involved in platelet reactivity, ag-
gregation, secretion and adhesion and there-
by plays essential role in the arterial throm-
botic conditions such as myocardial infarc-
tion (Nishiguchi et al., 2015). Another study 
demonstrated the indirect involvement of 
miR-96 in vascular diseases through modula-
tion of cholesterol metabolism via inhibition 
of selective high-density lipoprotein choles-
terol (HDL-C) uptake and SR-BI expression 
in human hepatic cells (Wang et al., 2013b). 
However, the role of BMP signalling in the 
miR-96-mediated effects was not explored.  
 
miR-143/145 
Kruppel-like factor-4 (KLF4) has been 
implicated in the phenotypic switch of SMCs 
through modulation of SMC contractile 
genes. Both TGF-β and BMP4 strongly re-
duces the expression of KLF4 through induc-
ing the expression of miR-143/145 in 
VSMCs (Davis-Dusenbery et al., 2011). In-
hibition of miR-145 by antagomiRs en-
hanced the expression of KLF4, which in 
turn increases expression of SMC contractile 
genes. Consistent with previous reports, 
these data suggests that KLF4 is pivotal for 
the TGF-β and BMP4-mediated phenotypic 
switch of SMCs. Although TGF-β and 
BMP4 enhance the expression of miR-
143/145 through the CArG box, TGF-β me-
diates its effects through up-regulation of 
myocardin whereas BMP4 triggers nuclear 
translocation of MRTF-A, indicating the po-
tential similarities and the differences of 
these pathways in modulation of KLF4-
mediated phenotypic switch of SMCs (Da-
vis-Dusenbery et al., 2011). 
Another report demonstrated that miR-
145 is expressed in SMCs of mouse lungs. 
Hypoxia, one of the triggers of PAH, also 
induces miR-145 expression in mouse lungs. 
Mice deficient for miR-145 and mice treated 
with inhibitors of miR-145 are resistant to 
the development of PAH. PASMCs derived 
from PAH patients with BMPR2 mutation 
showed enhanced expression of miR-145, 
suggesting that there is an inverse correlation 
between miR-145 expression and BMPR2 
levels. Interestingly, inhibitors of miR-143 
had no effect on PAH development (Caruso 
et al., 2012).  
 
miR-302 
The miR-302 family has been implicated 
in PAH. BMP4 decreases the expression of 
miR-302 in a Smad-dependent manner. 
Members of the miR-302 family have been 
shown to target BMPR2, which results in re-
duction in transcription of BMPR2 that leads 
to decreased BMP signalling in these cells. 
Overexpression of miR-302 decreases 
BMP4-mediated cell proliferation and migra-
tion which are two key characteristic features 
in PAH, suggesting that miR-302 might be 
beneficial in the treatment of PAH and other 
vascular proliferative diseases (Kang et al., 
2012b).  
 
OTHER VASCULAR CELLS 
miR-17/92 
VEGF has been shown to be a direct tar-
get of the miR-17/92 cluster which is regu-
lated by BMP signalling in the second heart 
field (SHF) that plays essential role in the 
outflow tract. Defects in outflow tract leads 
to congenital heart disease. Bai et al. (2013) 
also reported that deletion of BMP4 and 
BMP7 is associated with defective epithelial 
to mesenchymal transition (EMT) in which 
VEGF is a downstream effector of the BMP 
pathway. Overexpression of miR-17/92 can 
partially suppress EMT through regulation of 
VEGF. These data indicates that the miR-
17/92 cluster plays a crucial role in the out-
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flow tract through regulation of BMP path-
way and might be beneficial in the treatment 
of congenital heart disease. 
 
miR-155 
Numerous previous reports suggest that 
TGF-β and the angiotensin II type 1 receptor 
(AT1R) are associated in many pathologies 
including aneurysms and hypertension 
(Wolf, 1998; Gallo et al., 2014). AT1R has 
been identified as a miR-155 target gene 
(Zheng et al., 2010). miR-155 modulates ex-
pression of AT1R and plays a role in pheno-
typic differentiation of rat aortic adventitial 
fibroblasts (AFs). Ectopic expression of 
miR-155 inhibits AT1R 3′-UTR activity re-
porter activity and reduces protein levels of 
AT1R, but not mRNA levels. Although, 
overexpression of miR-155 inhibits Ang II-
induced αSMA expression, it did not influ-
ence TGF-β induced αSMA expression 
(Zheng et al., 2010).  
 
miR-181c 
Expression of miR-181c is induced in 
human cardiac samples from individuals 
with ventricular septal defects (VSDs), 
which leads to congenital heart defects 
(CHDs). Patients with VSDs show reduced 
expression levels of BMPR2, which is a pre-
dicted target of miR-181c. Indeed, overex-
pression of miR-181c down-regulated the 
expression of BMPR2. Because 80 % of he-
reditary PAH patients show mutations in 
BMPR2 accompanied by reduced levels of 
BMPR2 expression, it is helpful to investi-
gate the role of miR-181c on BMPR2 ex-
pression for the treatment of PAH (Li et al, 
2013).  
 
CONCLUSIONS AND PERSPECTIVES 
The TGF-β/BMP signalling plays crucial 
role in a wide-array of biological process, in-
cluding cell proliferation, migration and dif-
ferentiation. The discovery and functional 
characterization of miRs have led us to un-
derstand the cellular biology and their effect 
on diverse signalling pathways supports a 
role as pivotal regulators of cell function. 
There is compelling evidence shows that 
miRs are involved in pathogenesis of CVD 
and modulation of miRs has shown potential 
therapeutic benefit in distinct vascular dis-
eases. Both TGF-β and BMP signals modu-
late the expression of miRs. Conversely, 
miRs also regulate TGF-β/BMP signalling in 
vascular cells. The discovery of interaction 
between the TGF-β/BMP signalling and 
miRs in CVD is an exciting area of research. 
Understanding the underlying mechanism 
how TGF-β/BMP signalling modulates miRs 
and vice versa might be crucial for normal 
development, maintaining homeostasis, and 
treatment for vascular pathologies.  
In the current review, we summarized the 
miRs regulation of TGF-β/BMP signalling in 
vascular cells including ECs and SMCs, two 
key cell types involved in many vascular 
diseases. Many miRs target distinct compo-
nents of the TGF-β/BMP signalling such as 
Smad1, Smad4, Smad5, and BMPR2. This 
extensive information have led us to under-
stand the underlying mechanism through 
which miRs are integrated into the TGF-
β/BMP signalling. However, the functional 
roles of TGF-β/BMP signalling associated 
miRs in vascular cells still need to be ex-
plored in detail using in vivo models and pa-
tient samples. Although many miRs are as-
sociated with TGF-β/BMP signalling, there 
is still long way to go. Future studies are re-
quired to explore the interactions and precise 
mechanisms of the TGF-β/BMP signalling 
and miRs in CVD. Understanding this may 
help in the development of miRNA-based 
novel therapeutic approach through modulat-
ing the TGF-β/BMP signalling for patients 
with CVD. 
Cellular composition of the cardiovascu-
lar system changes under the diseased condi-
tions partly through modulation of TGF-
β/BMP signalling and results in differential 
expression patterns of miRs. Although the 
mechanisms modulating cellular composi-
tion and release of miRs are poorly under-
stood, circulating miRs are stable and may 
reflect the initiation and progression of the 
disease and could therefore useful as bio-
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marker to aid in diagnosis and monitoring 
disease progression and response to treat-
ment. Some of the major limitations in miR 
research is that lack of specificity and unpre-
dictable levels of miRs in vivo. These poten-
tial barriers must be overcome before their 
full therapeutic potential may be realized. 
Recent reports suggest that clinical applica-
tion of miRs is promising including the use 
of biomarkers and clinical trials with miR 
inhibitors. Although extensive in vitro data 
implicate a role of miRs in CVD, testing the 
miRs in vivo in disease models is essential. 
In conclusion, the involvement of miRs in 
regulation of TGF-β/BMP signalling in CVD 
warrant further genetic and pharmacological 
elucidation of their function in vivo in order 
to develop miRNA-based approaches for the 
prevention and treatment of cardiovascular 
disease. 
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